The Section 301 investigation turns a drug-pricing dispute into a trade fight, testing whether the Trump administration can use tariff law to pressure Germany and other wealthy markets to pay more for patented medicines. The case signals a broader effort to make foreign pharmaceutical reimbursement policy part of U.S. trade enforcement.
This item is available in full to subscribers.
To continue reading, you will need to either log in to your subscriber account, below, or purchase a new subscription.
If you are a current subscriber, and had an account on our previous site, you already have an account. If you have not yet logged into our new site, click here to reset your password.
Otherwise, click here to view your options for subscribing.
Please log in to continue |
